Compare TTEC & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTEC | FLNA |
|---|---|---|
| Founded | 1982 | 1998 |
| Country | United States | United States |
| Employees | 69400 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.0M | 61.8M |
| IPO Year | 1996 | 2000 |
| Metric | TTEC | FLNA |
|---|---|---|
| Price | $1.53 | $0.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.00 | ★ $6.50 |
| AVG Volume (30 Days) | 402.9K | ★ 702.8K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.80 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,509,171,000.00 | $41,119,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.15 | N/A |
| 52 Week Low | $1.18 | $0.64 |
| 52 Week High | $3.99 | $2.03 |
| Indicator | TTEC | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 34.93 |
| Support Level | $1.19 | N/A |
| Resistance Level | $2.84 | $1.05 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 52.70 | 3.74 |
TTEC Holdings Inc provides customer engagement management tools and services. The company operates through two operating segment, TTEC Digital and TTEC Engage. TTEC Digital is engaged in building and implementing cloud-based and on-premises customer experience tools that enable clients to develop customer engagement strategies. TTEC Engage focuses on delivering sales and marketing solutions to help clients boost their revenue as well as on managing customer's front-to-back office processes to optimize the customer experience. TTEC Engage contributes the vast majority of the company's revenue, and its revenues are derived from the United States and Canada, followed by Philippines, Asia-Pacific and India.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.